Biosimilars, Clovis' Rubraca among CHMP recommendations

EMA's CHMP recommended approval of a basket of therapies including cancer drug Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS), two biosimilars and HIV therapy Juluca dolutegravir/rilpivirine from ViiV Healthcare Ltd. (Brentford, U.K.).

CHMP backed Rubraca's conditional approval to treat platinum-sensitive, BRCA-mutant relapsed or progressive ovarian cancer in a third-line setting. The oral inhibitor of PARP-1, PARP-2 and PARP-3 has

Read the full 584 word article

User Sign In